Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing novel antiviral and pain-related therapies. Following its October 2024 combination, the company made Halneuron its lead program while continuing to evaluate IMC-1 and IMC-2 for herpesvirus-related disease burden, fibromyalgia, and Long-COVID-related fatigue.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaHalneuron® and related development work targeting pain and neuropathic conditions.
IMC-1 and IMC-2 fixed-dose combinations intended to suppress herpesvirus activation and replication.
Internal R&D, trial execution, and manufacturing support for pipeline advancement.
Out-licensing, collaboration, and partnership efforts to fund and advance programs.
Asiakkaat
Dogwood does not currently sell commercial products; its primary counterparties are clinical investigators, contract research and manufacturing partners, and potential licensing or development partners. The company’s future end customers would be patients with pain, fibromyalgia, Long-COVID fatigue, or herpesvirus-related disease, but near-term value creation depends on regulators and partners rather than product sales.
CROs, trial sites, and manufacturers that execute studies and supply drug product for Halneuron, IMC-1, and IMC-2.
Potential partners that could fund or co-develop IMC-1 and IMC-2 in exchange for rights or economics.
Patients with fibromyalgia, neuropathic pain, or Long-COVID fatigue who represent the eventual therapeutic market.
FDA and other stakeholders that determine approvable endpoints and development pathways.
Strategia
Dogwood’s strategy is to advance Halneuron as the lead program while preserving optionality on IMC-1 and IMC-2 through partnering and regulatory alignment. Near term, the company’s most important task is securing financing to continue clinical trials and avoid delaying development plans.
Cash is expected to fund operations only through the first quarter of 2026.
Halneuron is the lead program and the main focus of day-to-day operations.
Partnerships can offset development costs and improve the odds of progressing programs.
Maantiede
The company is headquartered in the United States and appears to conduct its core operations there. The disclosed business is development-stage and does not yet generate product revenue, so geography is mainly relevant through U.S.-based financing, clinical operations, and regulatory oversight rather than sales mix.
Riskit
Dogwood is a pre-revenue biotech with substantial going-concern risk, so its ability to fund trials is central to survival and value creation. Program risk is also high because clinical outcomes, FDA endpoint acceptance, and partner interest will determine whether Halneuron, IMC-1, or IMC-2 can advance. As with most development-stage pharmaceutical companies, dilution, trial delays, and regulatory uncertainty are major risks.
Cash on hand is expected to fund operations only through the first quarter of 2026.
Kohdistuu: All ongoing clinical trials and corporate operations
The company depends on successful trial execution to create value and attract partners.
Approval pathways depend on FDA agreement on endpoints and trial design.
Kohdistuu: IMC-2 Long-COVID development
The company needs collaboration or licensing deals to advance some programs efficiently.
Kohdistuu: IMC-1 Phase 3 partner search
Additional funding may come from equity or equity-linked securities.
Kohdistuu: Existing shareholders
Kirjanpito
Harkinnanvaraiset erätClinical trial, manufacturing, and personnel costs are expensed as incurred and drive operating loss volatility.
Vaikutus: Affects reported burn rate and comparability across periods
Registered direct offerings and loan proceeds include fees and issuance costs that reduce net financing inflows.
Vaikutus: Affects cash flow presentation and equity balances
Management must judge whether available cash and financing plans are sufficient for the next 12 months.
Vaikutus: Material disclosure affecting investor perception of solvency
Costs tied to the October 2024 combination flow through G&A and can distort period-to-period comparisons.
Vaikutus: Impacts operating expense trend
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Dogecoin Cash, Inc.
DOGP · Services-Personal Services
Longeveron Inc.
LGVN · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Inhibitor Therapeutics, Inc.
INTI · Pharmaceutical Preparations
Päivitetty: 24.9.2026